CKD-MBD: Impact on Management of Kidney Disease

Overview

Journal Clin Exp Nephrol

Publisher Springer

Specialty Nephrology

Date 2007 Dec 19

PMID 18085385

Citations 7

Authors

Hiroaki Ogata

Fumihiko Koiwa

Eriko Kinugasa

Tadao Akizawa

Affiliations

Soon will be listed here.

Abstract

Chronic kidney disease (CKD) causes various bone mineral disorders, which have recently been named CKD mineral and bone disorder (CKD-MBD). CKD-MBD is associated with extremely high cardiovascular disease (CVD) morbidity and mortality in the endstage kidney disease (ESKD) population. Thus, optimal management of CKD-MBD would lead to a reduction in cardiovascular morbidity and mortality in uremic patients. In addition, it has been suggested that the treatment of CKD-MBD has some favorable effects on the progression of CKD. Recently, novel therapeutic agents, including active vitamin D analogues, noncalcium-containing phosphate binders, and cinacalcet, have become clinically available. In this article, we review novel therapeutic strategies for CKD-MBD.

Citing Articles

The cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study.

Ogata H, Kumasawa J, Fukuma S, Mizobuchi M, Kinugasa E, Fukagawa M Clin Exp Nephrol. 2017; 21(5):797-806.

PMID: 28508128 PMC: 5648748. DOI: 10.1007/s10157-017-1380-2.

Design and baseline characteristics of the LANDMARK study.

Ogata H, Fukagawa M, Hirakata H, Kaneda H, Kagimura T, Akizawa T Clin Exp Nephrol. 2016; 21(3):531-537.

PMID: 27405619 PMC: 5556131. DOI: 10.1007/s10157-016-1310-8.

Clinical significance of parathyroid intervention on CKD-MBD management.

Ogata H, Mizobuchi M, Koiwa F, Kinugasa E, Akizawa T NDT Plus. 2015; 1(Suppl 3):iii9-iii13.

PMID: 25983977 PMC: 4421131. DOI: 10.1093/ndtplus/sfn080.

Limited referral to nephrologists from a tertiary geriatric outpatient clinic despite a high prevalence of chronic kidney disease and anaemia.

Boudville N, Muthucumarana K, Inderjeeth C BMC Geriatr. 2012; 12:43.

PMID: 22863034 PMC: 3441322. DOI: 10.1186/1471-2318-12-43.

Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism.

Tsuruta Y, Okano K, Kikuchi K, Tsuruta Y, Akiba T, Nitta K Clin Exp Nephrol. 2012; 17(1):120-6.

PMID: 22833360 DOI: 10.1007/s10157-012-0665-8.

References

Xiang W, Kong J, Chen S, Cao L, Qiao G, Zheng W . Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab. 2004; 288(1):E125-32. DOI: 10.1152/ajpendo.00224.2004. View

Block G, Levin N, Port F . Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998; 31(4):607-17. DOI: 10.1053/ajkd.1998.v31.pm9531176. View

De Santo N, Frangiosa A, Anastasio P, Marino A, Correale G, Perna A . Sevelamer worsens metabolic acidosis in hemodialysis patients. J Nephrol. 2006; 19 Suppl 9:S108-14. View

Shiizaki K, Negi S, Hatamura I, Sakaguchi T, Saji F, Kunimoto K . Biochemical and cellular effects of direct maxacalcitol injection into parathyroid gland in uremic rats. J Am Soc Nephrol. 2004; 16(1):97-108. DOI: 10.1681/ASN.2004030236. View

Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus J, Thadhani R . Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003; 349(5):446-56. DOI: 10.1056/NEJMoa022536. View

Nagano N, Miyata S, Obana S, Kobayashi N, Fukushima N, Burke S . Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency. Nephrol Dial Transplant. 2003; 18(10):2014-23. DOI: 10.1093/ndt/gfg309. View

Slatopolsky E, Brown A, Dusso A . Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl. 2000; 73:S14-9. DOI: 10.1046/j.1523-1755.1999.07304.x. View

Wu J, Garami M, Cheng T, Gardner D . 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest. 1996; 97(7):1577-88. PMC: 507220. DOI: 10.1172/JCI118582. View

Jono S, McKee M, Murry C, Shioi A, Nishizawa Y, Mori K . Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000; 87(7):E10-7. DOI: 10.1161/01.res.87.7.e10. View

10.

Li Y, Kong J, Wei M, Chen Z, Liu S, Cao L . 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002; 110(2):229-38. PMC: 151055. DOI: 10.1172/JCI15219. View

11.

Block G, Klassen P, Lazarus J, Ofsthun N, Lowrie E, Chertow G . Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15(8):2208-18. DOI: 10.1097/01.ASN.0000133041.27682.A2. View

12.

Amann K, Kronenberg G, Gehlen F, Wessels S, Orth S, Munter K . Cardiac remodelling in experimental renal failure--an immunohistochemical study. Nephrol Dial Transplant. 1998; 13(8):1958-66. DOI: 10.1093/ndt/13.8.1958. View

13.

Hirata M, Makibayashi K, Katsumata K, Kusano K, Watanabe T, Fukushima N . 22-Oxacalcitriol prevents progressive glomerulosclerosis without adversely affecting calcium and phosphorus metabolism in subtotally nephrectomized rats. Nephrol Dial Transplant. 2002; 17(12):2132-7. DOI: 10.1093/ndt/17.12.2132. View

14.

Ducy P, Zhang R, Geoffroy V, Ridall A, Karsenty G . Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. 1997; 89(5):747-54. DOI: 10.1016/s0092-8674(00)80257-3. View

15.

Tentori F, Hunt W, Stidley C, Rohrscheib M, Bedrick E, Meyer K . Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006; 70(10):1858-65. DOI: 10.1038/sj.ki.5001868. View

16.

Pfeifer M, Begerow B, Minne H, Nachtigall D, Hansen C . Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab. 2001; 86(4):1633-7. DOI: 10.1210/jcem.86.4.7393. View

17.

Fukagawa M, Akizawa T . Calcium abnormalities of dialysis patients. J Bone Miner Metab. 2006; 24(2):160. DOI: 10.1007/s00774-005-0663-y. View

18.

Tahara H, Tsujimoto Y, Shoji T, Inaba M, Tabata T, Nishizawa Y . Introduction to sevelamer hydrochloride and its clinical effects. Ther Apher Dial. 2005; 9 Suppl 1:S2-6. DOI: 10.1111/j.1744-9987.2005.00279.x. View

19.

Makibayashi K, Tatematsu M, Hirata M, Fukushima N, Kusano K, Ohashi S . A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol. 2001; 158(5):1733-41. PMC: 3277319. DOI: 10.1016/S0002-9440(10)64129-6. View

20.

Hutchison A, Speake M, Al-Baaj F . Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol Dial Transplant. 2004; 19(7):1902-6. DOI: 10.1093/ndt/gfh282. View